Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 7/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.30 |
| ▸ | WNT3A | P56704 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14189080 | 0.89 | PARP1 (0.54) | PARP1HTR1ASLC6A4 | |
| SCHEMBL20416982 | 0.81 | RAPGEF4 (0.35) | NOTUMCTNNB1WNT3ALMNA | |
| SCHEMBL4344995 | 0.81 | PARP1 (0.46) | PARP1HTR1ASLC6A4ALKNOTUM | |
| SCHEMBL3889397 | 0.78 | AKT1 (0.40) | NOTUMCTNNB1WNT3ALMNA | |
| SCHEMBL13534195 | 0.78 | NOTUM (0.38) | NOTUMPDE4A | |
| SCHEMBL7489213 | 0.78 | PARP1 (0.47) | PARP1HTR1ASLC6A4ALKNOTUM | |
| SCHEMBL6635190 | 0.78 | PARP1 (0.47) | PARP1HTR1ASLC6A4ALKNOTUM | |
| SCHEMBL14824890 | 0.78 | PARP1 (0.33) | PARP1HTR1ANOTUMPDE4ACTNNB1 | |
| SCHEMBL31472199 | 0.78 | NOTUM (0.32) | NOTUMCTNNB1WNT3A | |
| SCHEMBL16807804 | 0.77 | PARP1 (0.41) | PARP1HTR1ASLC6A4ALKNOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-8114866-B2 | Derivatives of 1-piperazine- and 1-homopiperazine-carboxylates, preparation method thereof and use of same as inhibitors of the FAAH enzyme | SANOFI-AVENTIS (FR) | 2012-02-14 | — | — | US | disclosed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI-EVENTIS (FR) | 2010-06-03 | — | — | US | disclosed |
| US-7687503-B2 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| US-7687503-B2 | 2-(methylamino)-2-oxoethyl 4-{5-[3-(trifluoromethyl)-phenyl]-2-pyridyl}-1-piperazinecarboxylate, for example; enzyme inhibitors of fatty acid amide hydrolases; treatment of pain, eating disorders, neurological and psychiatric pathologies, among other disorders | SANOFI-AVENTIS (FR) | 2010-03-30 | — | — | US | disclosed |
| EP-1701946-B1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | SANOFI AVENTIS (FR) | 2007-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137329-A1 | DERIVATIVES OF 1-PIPERAZINE- AND 1-HOMOPIPERAZINE-CARBOXYLATES, PREPARATION METHOD THEREOF AND USE OF SAME AS INHIBITORS OF THE FAAH ENZYME | FAAH, FAAH2, CNR1 | PARP1 1007/4885HTR1A 13/4885SLC6A4 1556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.